Affimed begins Phase I recruitment for anti-CD30 drug against Hodgkins

By Ross Bonander, November 17, 2010
Affimed.jpg

Germany-based biotech company Affimed Therapeutics has announced that they have begun Phase I enrollment for the company's anti-CD30 treatment for Hodgkins lymphoma (HL).

Read more about this at CancerTreatment.net.

disclaimer text

You May Also Want To Read

JCO.jpg
High BMI Associated With Improved Survival in DLBCL
According to the findings of a retrospective analysis of over 2,500 US military veterans diagnosed with diffuse large B-cell lymphoma (DLBCL) between...
Ibritumomab_tiuxetan_structure.jpg
Zevalin Added to SCT Boosts Survival in Refractory Follicular Lymphoma
Spectrum Pharmaceuticals is announcing that positive long-term clinical data for the Zevalin® therapeutic regimen has been published in the journa...
ASCO 2012.jpg
Treanda + Rituxan Wins Praise Over R-CHOP
Fewer side effects, a lower toxicity profile, and a better treatment outcome—all ideal hopes for cancer treatments, and according to a study presented...


Subscribe to Our Newsletter to Receive Lymphoma News and Support

Email

Learn More

tcell
Promising New Trial for Relapsed B-Cell Lymphoma
B cell lymphoma is notoriously unresponsive when it returns after treatment. Scientists at City of...
ASH-logo.jpg
Type 2 diabetes A Risk Factor For Blood Cancers
A meta-analysis led by researchers at the Miriam Hospital and published in the journal Blood found t...
Biovest.jpg
BiovaxID Demonstrates High Overall Survival in Mantle Cell Lymphoma
Biovest has announced that the National Cancer Institute (NCI) has presented outcomes at this past w...
Burkitt_lymphoma.jpg
Burkitt Lymphoma Much Different Than Other B-Cell Lymphomas
Scientists at the National Cancer Institute (NCI) have uncovered the first evidence that Burkitt lym...
zevalin.jpg
Phase III Trial Initiated for Radioimmunotherapy Zevalin Against DLBCL
Spectrum Pharmaceuticals, makers of the radioimmunotherapy treatment Zevalin, have announced the ini...
PANOBINOSTAT_IMG.gif
Panobinostat Could Benefit Some With Refractory Hodgkin's
According to research published recently in the Journal of Clinical Oncology, the investigational dr...

Poll

Why Did You Visit This Site?
Just Looking for Information
22%
I have Lymphoma/A loved one has lymphoma
66%
I am a lymphoma survivor
8%
I am a health care provider
3%
Total votes: 8981

LymphomaInfo Social

rss feed for lymphomainfo